Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

doi:10.1056/NEJMoa051918

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

The New England journal of medicine - 10 Nov 2005

Mellinghoff Ingo K, Wang Maria Y, Vivanco Igor, Haas-Kogan Daphne A, Zhu Shaojun, Dia Ederlyn Q, Lu Kan V, Yoshimoto Koji, Huang Julie H Y, Chute Dennis J, Riggs Bridget L, Horvath Steve, Liau Linda M, Cavenee Webster K, Rao P Nagesh, Beroukhim Rameen, Peck Timothy C, Lee Jeffrey C, Sellers William R, Stokoe David, Prados Michael, Cloughesy Timothy F, Sawyers Charles L, Mischel Paul S

Abstract excerpt

BACKGROUND: The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed, or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to EGFR kinase inhibitors. The mechanism of responsiveness of glioblastomas to these inhibitors is unknown. METHODS: We sequenced kinase domains in the EGFR and human EGFR type 2 (Her2/neu) genes and analyzed the expression of EGFR, EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, erbB-1

Share to Genes, erbB-2

Share to Glioblastoma

Share to Oligodendroglioma

Share to PTEN Phosphohydrolase

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 16282176
DOI: 10.1056/NEJMoa051918

Genes

EGFR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.PMID 16282176Read ↗

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Semantic proximity Read ↗

Expression of EGFRvIII in Glioblastoma: Prognostic Significance RevisitedSemantic proximity Read ↗

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.Semantic proximity Read ↗

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.Semantic proximity Read ↗

Personalized medicine for glioblastoma: current challenges and future opportunities.Semantic proximity Read ↗

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.Semantic proximity Read ↗

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Semantic proximity Read ↗

EGFR as a clinical marker in glioblastomas and other gliomas.Semantic proximity Read ↗

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.Semantic proximity Read ↗

Epidermal growth factor receptor as a therapeutic target in glioblastoma.Semantic proximity Read ↗

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysisSemantic proximity Read ↗

PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.